Thomas Smith
Stock Analyst at Leerink Partners
(2.23)
# 2,782
Out of 5,143 analysts
63
Total ratings
35.71%
Success rate
10.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $58 | $57.93 | +0.12% | 4 | Jan 21, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $6.80 | +76.47% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $28.08 | +13.96% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $27.88 | +50.65% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.92 | -47.92% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $4.50 | +100.00% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.36 | +108.33% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.55 | +416.56% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $5.92 | +339.19% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $128.29 | -84.41% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $840.28 | -48.23% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $66.20 | -45.62% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.45 | +185.71% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $27.39 | -23.33% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $29.40 | +53.06% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $11.28 | -46.81% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.54 | +8.30% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.90 | +456.61% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $18.20 | -6.59% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $24.84 | +157.65% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.13 | +286.10% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.45 | +961.22% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $33.75 | -64.44% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $31.75 | +1,159.84% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $15.52 | +415.46% | 2 | Dec 8, 2020 |
RAPT Therapeutics
Jan 21, 2026
Downgrades: Market Perform
Price Target: $58
Current: $57.93
Upside: +0.12%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $6.80
Upside: +76.47%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $28.08
Upside: +13.96%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $27.88
Upside: +50.65%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.92
Upside: -47.92%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $4.50
Upside: +100.00%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.36
Upside: +108.33%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.55
Upside: +416.56%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $5.92
Upside: +339.19%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $128.29
Upside: -84.41%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $840.28
Upside: -48.23%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $66.20
Upside: -45.62%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.45
Upside: +185.71%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $27.39
Upside: -23.33%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $29.40
Upside: +53.06%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $11.28
Upside: -46.81%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.54
Upside: +8.30%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.90
Upside: +456.61%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $18.20
Upside: -6.59%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $24.84
Upside: +157.65%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.13
Upside: +286.10%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.45
Upside: +961.22%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $33.75
Upside: -64.44%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $31.75
Upside: +1,159.84%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $15.52
Upside: +415.46%